Thursday, 5 January 2017

Japanese Pharma Cos Back with New Products

Get highest number of drug approvals last year, beating US and Swiss competitors
After burning their fingers more than once in India with troubled acquisitions, Japanese drug makers are back in this market, this time through the age-old route of product launches.
Japanese companies received the highest number of drug approvals from the Drug Controller General of India in 2016, beating their American and Swiss competitors.
Out of 20 approvals that came in the past year, five went to four Japanese companies: Eisai, Takeda, Dainippon Sumitomo and Mitsubishi Tanabe.
“Most (Japanese) organisations are of the view that it is better to go alone or through collaborations instead of going the acquisition route,“ said Sanjit Lamba, the India head of Eisai Pharmaceuticals.“For Eisai, this year is going to be significant as after the Halavan (a breast cancer drug) launch in 2013, this year we will see multiple drug launches,“ he added. In India, Ei sai is expected to launch anti-epilepsy drug Perampanel that is sold under the brand name Fycompa.This is the first drug for epilepsy that was approved by the US regulator in eight years. Eisai has also got an approval in India for Lenva tinib, a drug to treat thyroid cancer.
The other drugs that received pproval are Azilsartan, a hypertension drug by Takeda, Bepotastine for eye infection by Mitsubishi Tanabe and Lurasidone by Dainippon Sumitomo for the treatment of bipolar disorder.
The Indian regulators have assured Japanese drug companies that their filings will get special attention and they will also be given help to make the filings, said Appaji Rao, director general of Pharmexil, the Indian government agency that looks at promotion of pharma exports. “This was after an MoU (memorandum of understanding) was signed between the Indian and Japanese drug regulators.“

Source: THE ECONOMIC TIMES-4th January,2017